May 23, 2015
Below are current clinical trials.479 studies in Cancer
(open studies only).
Filter this list of studies by location, status and more.
This phase II trial studies how well pembrolizumab and ibrutinib work in treating patients with stage III-IV melanoma that cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and ibrutinib may work better in treating patients with melanoma.
The purpose of this study is to evaluate the Maximum Tolerated Dose (MTD) of pralatrexate in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen in patients with newly diagnosed peripheral T-cell lymphoma (PTCL).
Scottsdale/Phoenix, Ariz., Rochester, Minn.
The purpose of the study is to evaluate progression free survival, using independent radiologic review, of ASP8273 compared to erlotinib or gefitinib in patients with locally advanced, metastatic or unresectable stage IIIB/IV adenocarcinoma non-small cell lung cancer that has epidermal growth factor receptor (EGFR) activating mutations.
This study will also assess overall survival, overall response rate, progression free survival assessed by the investigator, disease control rate, duration of response, safety of ASP8273, quality of life, and patient-reported outcome parameters.
Scottsdale/Phoenix, Ariz., Rochester, Minn.
This randomized phase III trial has several primary objectives. One primary objective is to compare the efficacy of 3 different endocrine therapies, the estrogen receptor down regulator fulvestrant and the aromatase inhibitor anastrozole, either alone or in combination, in reducing cancer growth before surgery (neoadjuvant) in postmenopausal women with clinical stage II-III estrogen receptor positive and HER2 negative breast cancer. Another primary objective is to evaluate whether patients who achieved a modified PEPI (Preoperative Endocrine Prognostic Index) score of 0, defined by tumor size <5 cm, N0, Ki67<2.7% (by central testing), at surgery post 6 months of neoadjuvant endocrine therapy predict excellent long term outcome, for whom chemotherapy is unnecessary.
The purpose of this registry is to collect and maintain samples of breast tissue from women and men undergoing surgery for a breast related concern at Mayo Clinic Rochester, to create a biospecimen resource for the study of benign and cancerous breast conditions.
The standard treatment for locally advanced rectal cancer involves chemotherapy and radiation, known as 5FUCMT, (the chemotherapy drugs 5-fluorouracil/capecitabine and radiation therapy) prior to surgery. Although radiation therapy to the pelvis has been a standard and important part of treatment for rectal cancer and has been shown to decrease the risk of the cancer coming back in the same area in the pelvis, some patients experience undesirable side effects from the radiation and there have been important advances in chemotherapy, surgery, and radiation which may be of benefit. The purpose of this study is to compare the effects, both good and bad, of the standard treatment of chemotherapy and radiation to chemotherapy using a combination regimen known as FOLFOX, (the drugs 5-fluorouracil (5-FU), oxaliplatin and leucovorin) and selective use of the standard treatment, depending on response to the FOLFOX. The drugs in the FOLFOX regimen are all FDA (Food and Drug Administration) approved and have been used routinely to treat patients with advanced colorectal cancer.
The purpose of this study is to evaluate the safety of alisertib and its effect, bad and/or good, on acute megakaryoblastic leukemia (AMKL) or myelofibrosis (MF). The study drug, alisertib, is an investigational drug. An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). Alisertib has shown evidence in the lab that it may have an effect on a type of cell that produces platelets. This cell is called a megakaryocyte and it is known to be defective (doesn't work well) in both AMKL and MF.
This phase III trial studies the side effects and how well risk-based therapy works in treating younger patients with newly diagnosed liver cancer. Surgery, chemotherapy drugs (cancer fighting medicines), and when necessary liver transplant are the main current treatments for hepatoblastoma. The stage of the cancer is one factor used to decide the best treatment. Treating patients according to the risk group they are in may help get rid of the cancer, keep it from coming back, and decrease the side effects of chemotherapy.
This pilot research trial studies blood brain barrier differences in patients with brain tumors undergoing surgery. Studying samples of tissue and blood from patients with brain tumors in the laboratory may help doctors to understand how well drugs get into different parts of a brain tumor. This may help them to determine which types of drugs may be best for treating brain tumors.
The purpose of this study is to compare the effect of a blood thinning drug called Apixaban versus no administration of a blood thinning drug, in preventing blood clots in children with leukemia or lymphoma. Patients must be receiving chemotherapy; including Pegylated L-Asparaginase and have a central line (a catheter inserted for administration of medications and blood sampling).
- Deaths and mortality. Centers for Disease Control and Prevention. http://www.cdc.gov/nchs/fastats/deaths.htm. Accessed April 23, 2015.
- Cancer: All sites. Surveillance Epidemiology and End Results. http://seer.cancer.gov/statfacts/html/all.html. Accessed April 23, 2015.
- Symptoms. National Cancer Institute. http://www.cancer.gov/cancertopics/diagnosis-staging/symptoms. Accessed April 23, 2015.
- Kushi LH, et al. American Cancer Society guidelines on nutrition and physical activity for cancer prevention: Reducing the risk of cancer with healthy food choices and physical activity. CA: A Cancer Journal for Clinicians. 2012;62:30.
- Niederhuber JE, et al., eds. Genetic and epigenetic alterations in cancer. In: Abeloff's Clinical Oncology. 5th ed. Philadelphia, Pa.: Churchill Livingstone Elsevier; 2014. http://www.clinicalkey.com. Accessed April 23, 2015.
- Ulcerative colitis. National Institute of Diabetes and Digestive and Kidney Diseases. http://digestive.niddk.nih.gov/ddiseases/pubs/colitis/index.htm. Accessed April 23, 2015.
- NINDS paraneoplastic syndromes information page. National Institute of Neurological Disorder and Stroke. http://www.ninds.nih.gov/disorders/paraneoplastic/paraneoplastic.htm. Accessed April 23, 2015.
- Deng GE, et al. Evidence-based clinical practice guidelines for integrative oncology: Complementary therapies and botanicals. Journal of the Society for Integrative Oncology. 2009;7:85.
- Taking time: Support for people with cancer. National Cancer Institute. http://cancer.gov/cancertopics/takingtime. Accessed April 23, 2015.
- Moynihan TJ (expert opinion). Mayo Clinic, Rochester, Minn. May 1, 2015.
- Hypercalcemia (high level of calcium in the blood). Merck Manual Home Edition. http://www.merckmanuals.com/home/hormonal-and-metabolic-disorders/electrolyte-balance/hypercalcemia-high-level-of-calcium-in-the-blood. Accessed April 23, 2015.
- What is cancer? National Cancer Institute. http://www.cancer.gov/cancertopics/what-is-cancer. Accessed April 23, 2015.
- Cancer prevention overview (PDQ). National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/prevention/overview/patient/page1/AllPages. Accessed April 23, 2015.
- The genetics of cancer. National Cancer Institute. http://www.cancer.gov/cancertopics/causes-prevention/genetics. Accessed April 23, 2015.
- Understanding cancer risk. Cancer.Net. http://www.cancer.net/navigating-cancer-care/prevention-and-healthy-living/understanding-cancer-risk. Accessed April 23. 2015.
- Cancer screening overview (PDQ). National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/screening/overview/HealthProfessional. Accessed April 23, 2015.
- Diagnosis. National Cancer Institute. http://www.cancer.gov/cancertopics/diagnosis-staging/diagnosis. Accessed April 23, 2015.
- Staging. National Cancer Institute. http://www.cancer.gov/cancertopics/diagnosis-staging/staging. Accessed April 23, 2015.
- Making decisions about cancer treatment. Cancer.Net. http://www.cancer.net/navigating-cancer-care/how-cancer-treated/making-decisions-about-cancer-treatment. Accessed April 23, 2015.
- How cancer is treated. Cancer.Net. http://www.cancer.net/navigating-cancer-care/how-cancer-treated. Accessed April 23, 2015.